首页|流体动力学基因转染技术构建BGJ398耐药原位肝内胆管癌小鼠模型

流体动力学基因转染技术构建BGJ398耐药原位肝内胆管癌小鼠模型

扫码查看
目的:构建一种BGJ398耐药的原位肝内胆管癌(intrahepatic cholangiocarcinoma,ICC)小鼠模型,以模拟临床患者的成纤维生长因子受体2(fibroblast growth factor receptor 2,FGFR2)基因重排/融合突变及FGFR2激酶结构域突变,为相关研究提供工具.方法:通过流体动力学尾静脉注射技术向小鼠注射pT3-myr-AKT-HA、pT3-EF1a-NICD1、pCMV(CAT)T7-SB100和pSB[Exp]-myr-FGFR2-FLAG等质粒,将易于磷酸化的FGFR2的基因引入小鼠肝脏,构建BGJ398敏感性原位ICC小鼠模型,随后对部分小鼠进行BGJ398连续给药4周以诱导小鼠的耐药性,从而建立BGJ398耐药性原位ICC小鼠模型;应用超声成像监测胆道梗阻病灶以分析小鼠模型对BGJ398的耐药程度;观察模型小鼠的肝脏组织并对肝脏组织切片进行HE染色和油红O染色以分析BGJ398耐药原位ICC模型的组织学特征;应用免疫荧光染色法分析BGJ398耐药小鼠ICC原位肿瘤细胞的来源;提取原代肿瘤细胞,应用CCK-8法测定肿瘤细胞对BGJ398的敏感度和BGJ398对肿瘤细胞的半数抑制浓度(median inhibition concentration,IC50);用BGJ398对构建的小鼠模型进行治疗并绘制生存曲线以在体内验证原位ICC模型的耐药性;提取耐药性原位ICC组织的DNA,进行基因组重测以序验证FGFR2激酶结构域序列的突变.结果:BGJ398耐药的原位ICC小鼠模型构建成功率达93.33%,肝脏表现出显著的肿瘤负荷,肝组织内可见ICC组织呈腺管状排列;肝组织切片HE染色和油红O染色显示出大量脂滴空泡;肝组织免疫荧光染色结果显示,所有肿瘤细胞中胆管上皮细胞标志物细胞角质蛋白19(cytokeratin 19,CK19)的表达均呈阳性,而肝细胞标志物白蛋白(albumin,ALB)的表达均呈阴性;提取并培养ICC原代肿瘤细胞,CCK-8实验结果显示BGJ398 在敏感细胞中的IC50 值为 95.22 nmol,而在耐药细胞的IC50 值增至348.4 nmol;对敏感或耐药模型小鼠进行BGJ398腹腔注射治疗后发现,耐药小鼠的生存率显著低于敏感组(P=0.001 7);基因组重测序分析结果揭示了FGFR2基因中的显著突变,明确验证了所构建BGJ398耐药原位ICC小鼠模型与临床ICC患者的基因突变一致性.结论:本研究成功构建了一种BGJ398耐药的原位ICC小鼠模型,为进一步探索FGFR抑制剂耐药的分子机制和开发新的治疗方法提供了重要的工具.
Construction of an orthotopic mouse model of intrahepatic cholangiocarcinoma resistant to BGJ398 using hydrodynamic injection
Objective:To establish a BGJ398-resistant orthotopic model of intrahepatic cholangiocarcinoma(ICC)in mice that simulates the fibroblast growth factor receptor 2(FGFR2)gene rearrangement/fusion mutations and FGFR2 kinase domain mutations in clinical patients,in order to provide a tool for relavant research.Methods:Modified FGFR2 gene encoding FGFR2 protein that's prone to phosphorylation activation was introduced into the mouse liver using hydrodynamic tail vein injection technology to establish a BGJ398-sensitive orthotopic model of ICC.Plasmids injected include pT3-myr-AKT-HA,pT3-EF1a-NICD1,pCMV(CAT)T7-SB100 and pSB[Exp]-myr-FGFR2-FLAG.Then,the mice were treated with BGJ398 for 4 weeks to induce resistance to BGJ398.Ultrasound imaging was used to monitor bile duct obstruction lesions in the model mice in order to access the extent of resistance to BGJ398.HE staining and oil red O staining were used to analyze liver tissue sections for the histological features of the BGJ398-resistant orthotopic ICC model.Immunofluorescence staining was used to analyze the origin of the ICC cells from BGJ398-resistant mice.Primary tumor cells were extracted from the model mice and CCK-8 assay was performed to analyze their sensitivity to BGJ398 in vitro as well as the median inhibition concentration(IC50)of BGJ398.The model mice were treated with BGJ398 and the survival curves were plotted to verify the resistance of the ICC mouse model to drug treatment in vivo.DNA was extracted from drug-resistant ICC tissues and genomic resequencing was used to verify mutations in the kinase domain of the FGFR2 sequence.Results:The successful rate of the BGJ398-resistant orthotopic ICC mouse model construction was 93.33%,with significant tumor burden observed in the liver.Histologically,ICC tumor tissue was arranged in glandular duct patterns in the liver.Large numbers of lipid droplet vacuoles appeared in HE staining and oil red O staining.Immunofluorescence staining of the liver tissue showed positive results for biliary epithelial cell marker cytokeratin 19(CK19)and negative results for hepatocyte marker albumin(ALB).Primary ICC tumor cells were extracted and cultured,and CCK-8 results showed that the IC50 value for BGJ398 was 95.22 nmol in BGJ398-sensitive cells while the number increased to 348.4 nmol in BGJ398-resistant cells.After treatment with BGJ398 through intraperitoneal injection,the survival rate for BGJ398-resistnat mice was significantly lower than that of BGJ398-sensitive mice(P=0.001 7).Subsequent genomic resequencing revealed significant mutations in the FGFR2 gene,verifying that the mutations in the orthotopic ICC mouse model was consistent with those found in clinical ICC patients.Conclusion:This study has successfully established a BGJ398-resistant orthotopic ICC mouse model,providing valuable tools for further exploration of the molecular mechanisms of resistance to FGFR inhibitors and the development of new treatment methods.

Intrahepatic cholangiocarcinomaDrug resistance mechanismFGFR inhibitorGene rearrangementKinase domain mutation

段诣、朱晏、段友容、孙颖

展开 >

上海交通大学医学院附属仁济医院上海市肿瘤研究所肿瘤系统医学全国重点实验室,上海 200032

肝内胆管癌 耐药机制 FGFR抑制剂 基因重排 激酶结构域突变

2024

肿瘤
上海市肿瘤研究所

肿瘤

CSTPCD
影响因子:1.112
ISSN:1000-7431
年,卷(期):2024.44(5)